Lecture 9-3: Genetic Technology, Enhancement, and Creaturely Limits

Romans 9:21 — "Or hasn't the potter a right over the clay, from the same lump to make one part a vessel for honor, and another for dishonor?" (World English Bible)

John 9:3 — "Jesus answered, 'Neither did this man sin, nor his parents; but, that the works of God might be revealed in him.'" (WEB)

2 Corinthians 12:9 — "He has said to me, 'My grace is sufficient for you, for my power is made perfect in weakness.' Most gladly therefore I will rather glory in my weaknesses, that the power of Christ may rest on me." (WEB)

3.1 Therapy and enhancement: a real distinction, an unclean edge

The standard distinction in bioethics separates therapeutic intervention — correcting or treating a departure from species-typical function, such as editing the gene responsible for sickle cell disease or cystic fibrosis — from enhancement — improving a capacity beyond the species-typical range in someone who was not, by any ordinary medical definition, ill: increasing height, cognitive processing speed, or muscular strength beyond what any disease process had impaired. The distinction earns its keep because it tracks something real: treating a person with a genetic disease restores a capacity that disease has taken or would take from them, while enhancing an already-typical capacity is a different kind of act, aimed at a different kind of goal, even when the underlying technology (gene editing) is identical in both cases.

The difficulty is that "species-typical function" is not a sharp, self-evident line, and several real cases sit uncomfortably on or across it. Consider gene therapy aimed at increasing bone density in a patient with a bone-density level within the normal range but at its low end, who has suffered several fractures — is this treating a real, if statistically unremarkable, vulnerability, or enhancing a trait that was never diagnosably diseased? Consider a genetic intervention that would prevent a late-onset condition (such as a strongly heritable form of dementia) decades before any symptom would appear — is intervening on a currently healthy person's genome to prevent a disease that has not yet manifested therapy (because the disease process, genetically speaking, is already present and progressing) or something closer to enhancement (because the patient, examined today, shows no illness at all)? These are not manufactured puzzles; they are the actual cases genetic medicine is confronting as its tools become more precise, and a bioethics that pretends the therapy/enhancement line resolves them cleanly is not being honest about its own key distinction. This lecture uses the distinction because it remains useful for the clearer cases at its center — sickle cell gene therapy is therapy, and height-enhancement gene editing in an already-typical child is enhancement — while acknowledging its edges are genuinely contested.

3.2 The potter's authority, extended to the genome

Romans 9:21 was introduced in lecture 4-2 as a guardrail against "co-creator" language sliding into a claim that erases the Creator/creature distinction: "hasn't the potter a right over the clay, from the same lump to make one part a vessel for honor, and another for dishonor?" (WEB). Paul's argument in its original context concerns God's sovereign freedom in election, a considerably narrower and more specific claim than this lecture is about to draw from it — a caution worth stating plainly rather than papering over. What this lecture extracts from the image is not Paul's doctrine of election but the structural relationship the image assumes: the potter, not the clay, holds the authority to determine the clay's shape and purpose, and the clay's proper posture toward that shaping is not self-determination but reception.

Applied to genetic self-authorship, the caution is this: treating the human genome as raw material available for whatever shape a person, a parent, or a society happens to prefer implicitly reverses the potter/clay relationship the text assumes, making the human being (or the human being's engineers) the potter of the human genome rather than the clay in the hands of God. This does not, by itself, forbid every genetic intervention — a physician setting a broken bone or removing a diseased organ is not thereby claiming the authority of a potter over the whole shape of a life, and this lecture has already argued therapeutic genetic correction sits comfortably alongside those interventions. The caution bites specifically at unlimited genetic self-design — engineering offspring according to a preferred profile of traits with no relationship to disease or disability — where the underlying logic treats a human genome as a medium for someone else's preferences rather than as a given a person receives.

3.3 A hard text: not every limitation is a problem to be engineered away

John 9 records the healing of a man born blind, and the disciples' question to Jesus assumes a framework this lecture wants to name and set aside: "who sinned, this man or his parents, that he was born blind?" (John 9:2), a question that treats disability as necessarily the effect of a prior moral failure requiring an explanation. Jesus's answer refuses the question's premise entirely: "Neither did this man sin, nor his parents; but, that the works of God might be revealed in him" (John 9:3, WEB).

This text is genuinely difficult, and this lecture will not soften it into easier comfort than it offers. It does not say blindness is good, or that healing it is unnecessary — the chapter's very next verses show Jesus healing the man. What it refuses is the assumption, prior to any healing, that the man's blindness stood in need of a moral explanation, and it locates meaning — "the works of God" — in a limitation Jesus is about to heal rather than treating the limitation's mere existence as a wrong to be corrected as quickly as technology allows, as though its only possible meaning were absence-of-a-fix.

Applied to genetic technology, this text pushes against a background assumption easy to absorb from a culture confident in its ability to engineer away difficulty: that every departure from a statistically typical genome is, simply as such, a problem awaiting a technical solution, and that a person living with such a departure is a project incompletely finished. John 9:3 will not support that assumption, without thereby opposing legitimate medical treatment of disease — a distinction this lecture insists on holding together rather than collapsing in either direction. 2 Corinthians 12:9 supplies the same caution from Paul's own experience: after asking three times for his unspecified "thorn in the flesh" to be removed, Paul reports God's answer — "my grace is sufficient for you, for my power is made perfect in weakness" (WEB) — and Paul's own response is not resignation but something closer to reframing: "I will rather glory in my weaknesses, that the power of Christ may rest on me." Paul had asked for healing and did not receive it; the text does not thereby conclude that asking was wrong, or that all limitation should be sought after rather than treated.

Held together, John 9:3 and 2 Corinthians 12:9 resist two opposite errors this course wants to name explicitly. The first error is treating every limitation as a problem technology is obligated to solve, which these texts push back against. The second, equally serious error is inverting that caution into a romanticized fatalism — treating any use of medical technology to relieve suffering as a failure of faith or an insufficient acceptance of God's providence, which neither text states and which would make Jesus's own healing ministry throughout the Gospels inexplicable. A fair reading holds: some limitations become, in ways a person may not choose or welcome but can come to recognize, the site of God's glory or grace rather than merely an unfinished repair; and treatable illness remains rightly treatable. The two texts do not tell a reader in advance which category a given case falls into — that discernment belongs to the person living with the limitation, not to a general theological rule applied from outside.

3.4 Where Christian bioethicists genuinely divide

This lecture's argument so far — therapy is legitimate, unlimited self-design oversteps creaturely limits, and not every limitation is a problem awaiting an engineered fix — leaves a real and disputed question unanswered: is there a category of limited, careful genetic enhancement (not therapy, by the definition in 3.1) that a faithful Christian bioethics could accept?

Some Christian bioethicists answer yes, at least in principle. Their argument typically runs: if enhancing a capacity through non-genetic means (education, nutrition, training, even some pharmacological aids to concentration) is uncontroversially compatible with Christian faith, and if the moral difference between a genetic and a non-genetic means of achieving the same enhanced capacity is not obviously itself morally significant, then a carefully limited, safety-conscious genetic enhancement — for instance, an intervention modestly reducing a well-documented genetic risk factor for a common late-life cognitive decline, in a way that also happens to improve a currently-healthy person's baseline cognitive resilience — need not itself cross into the Romans 9:21 concern about self-authorship, provided it remains modest, safety-tested, and does not aim at manufacturing a preferred "type" of person.

Other Christian bioethicists answer no, and hold that any enhancement beyond therapy — however modest — oversteps creaturely limits in a way therapy does not, because enhancement's aim is definitionally different: it does not restore a person to their own species-typical function but reaches past it toward a preference, and a preference is exactly the kind of thing Romans 9:21's potter, not the clay, has authority to determine. On this view, the very carefulness and modesty of a "limited" enhancement does not change its kind, only its degree, and conceding that some degree of enhancement is acceptable opens a door this position holds should stay closed as a matter of principle rather than case-by-case negotiation.

This lecture does not resolve this dispute, and it would misrepresent the actual, serious disagreement among faithful Christian bioethicists to claim one side is obviously right. Both positions accept everything argued in 3.1 through 3.3: that therapy for disease is good, that unlimited self-design oversteps creaturely limits, and that not every limitation is a problem. They divide specifically and only on whether a narrow middle category — limited, careful, non-self-authorship-aiming enhancement — exists as a legitimate space between those two poles, or whether the therapy/enhancement line itself is the only defensible boundary and any crossing of it, however modest, is a crossing too far. A student encountering this debate for the first time should resist the temptation to assume the more restrictive position is automatically the more faithful one, or that the less restrictive position is automatically a capitulation to secular values; both are argued, by serious Christian thinkers, from inside the same shared theological commitments this lecture has laid out.